Your browser doesn't support javascript.
loading
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season.
Dagan, Ron; Hammitt, Laura L; Seoane Nuñez, Beatriz; Baca Cots, Manuel; Bosheva, Miroslava; Madhi, Shabir A; Muller, William J; Zar, Heather J; Chang, Yue; Currie, Alexander; Grenham, Amy; Shroff, Manish; Takas, Therese; Mankad, Vaishali S; Leach, Amanda; Villafana, Tonya.
Afiliación
  • Dagan R; The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences at the Ben-Gurion University of the Negev, Beer-Sheva, Israel.
  • Hammitt LL; Department of International Health, Johns Hopkins University, Baltimore, Maryland, USA.
  • Seoane Nuñez B; Biometrics, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Madrid, Spain.
  • Baca Cots M; Paediatric Service, Quirónsalud Málaga Hospital, Málaga, Spain.
  • Bosheva M; Paediatrics, University Multiprofile, Hospital for Active Treatment, St. George Medical University, Plovdiv, Bulgaria.
  • Madhi SA; South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Muller WJ; Infectious Diseases, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois, USA.
  • Zar HJ; Stanley Manne Children's Research Institute, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Chang Y; Department of Paediatrics and Child Health, Red Cross Children's Hospital, and the Medical Research Council Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa.
  • Currie A; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Grenham A; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
  • Shroff M; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Takas T; Patient Safety, Chief Medical Office, R&D, AstraZeneca, Waltham, Massachusetts, USA.
  • Mankad VS; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
  • Leach A; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Durham, North Carolina, USA.
  • Villafana T; Clinical Development, Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, Maryland, USA.
J Pediatric Infect Dis Soc ; 13(2): 144-147, 2024 Feb 26.
Article en En | MEDLINE | ID: mdl-38219024
ABSTRACT
To characterize nirsevimab in the prevention of RSV, children from the Phase 3 MELODY trial were followed through their second RSV season. No increase in medically attended RSV lower respiratory tract infections or evidence of antibody-dependent enhancement of infection or disease severity was found for nirsevimab vs placebo recipients. Clinical Trial Registration Clinicaltrials.gov, NCT03979313, https//clinicaltrials.gov/ct2/show/NCT03979313.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Virus Sincitial Respiratorio Humano / Infecciones por Virus Sincitial Respiratorio Tipo de estudio: Clinical_trials Límite: Child / Humans / Infant Idioma: En Revista: J Pediatric Infect Dis Soc Año: 2024 Tipo del documento: Article País de afiliación: Israel
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones del Sistema Respiratorio / Virus Sincitial Respiratorio Humano / Infecciones por Virus Sincitial Respiratorio Tipo de estudio: Clinical_trials Límite: Child / Humans / Infant Idioma: En Revista: J Pediatric Infect Dis Soc Año: 2024 Tipo del documento: Article País de afiliación: Israel